PubRank

P Scheltens

Author PubWeight™ 244.22‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Consistent resting-state networks across healthy subjects. Proc Natl Acad Sci U S A 2006 19.60
2 A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001 5.81
3 Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997 3.87
4 Graph theoretical analysis of magnetoencephalographic functional connectivity in Alzheimer's disease. Brain 2008 3.36
5 Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. Neuroimage 2004 3.25
6 Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. J Neurol 1999 2.92
7 Incident lacunes influence cognitive decline: the LADIS study. Neurology 2011 2.81
8 Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 2000 2.56
9 Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007 2.47
10 Association of gait and balance disorders with age-related white matter changes: the LADIS study. Neurology 2008 2.41
11 Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment. J Neurol Neurosurg Psychiatry 2002 2.41
12 Prevalence and severity of microbleeds in a memory clinic setting. Neurology 2006 2.29
13 EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol 2010 2.21
14 Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998 2.17
15 Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study. J Neurol Neurosurg Psychiatry 2000 1.97
16 Diagnosis and management of Alzheimer's disease and other disorders associated with dementia. The role of neurologists in Europe. European Federation of Neurological Societies. Eur J Neurol 2000 1.89
17 Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology 2009 1.88
18 Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. Brain 2008 1.84
19 CT and MRI rating of white matter lesions. Cerebrovasc Dis 2002 1.83
20 Visual rating of age-related white matter changes on magnetic resonance imaging: scale comparison, interrater agreement, and correlations with quantitative measurements. Stroke 2003 1.78
21 Unbiased whole-brain analysis of gray matter loss in Alzheimer's disease. Neurosci Lett 2000 1.77
22 Familial aggregation in frontotemporal dementia. Neurology 1998 1.76
23 The seven minute screen: a neurocognitive screening test highly sensitive to various types of dementia. J Neurol Neurosurg Psychiatry 2004 1.73
24 The effect of APOE genotype on clinical phenotype in Alzheimer disease. Neurology 2006 1.71
25 [Acute subdural hematoma following minor head injury]. Ned Tijdschr Geneeskd 1992 1.69
26 Hippocampal atrophy in Alzheimer disease: age matters. Neurology 2006 1.66
27 Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy. Diabetologia 2006 1.66
28 Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: a 3-year follow-up of the LADIS study cohort. J Neurol Sci 2011 1.66
29 A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem 2009 1.66
30 Magnetoencephalographic evaluation of resting-state functional connectivity in Alzheimer's disease. Neuroimage 2006 1.64
31 Longitudinal changes of CSF biomarkers in memory clinic patients. Neurology 2007 1.57
32 Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 2011 1.56
33 Cortico-hippocampal communication by way of parallel parahippocampal-subicular pathways. Hippocampus 2000 1.55
34 Functional MR imaging in Alzheimer's disease during memory encoding. AJNR Am J Neuroradiol 2001 1.54
35 Circadian rest-activity rhythm disturbances in Alzheimer's disease. Biol Psychiatry 1996 1.54
36 Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005 1.53
37 Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. Brain 1998 1.52
38 Amnestic mild cognitive impairment: structural MR imaging findings predictive of conversion to Alzheimer disease. AJNR Am J Neuroradiol 2008 1.50
39 Measuring progression of cerebral white matter lesions on MRI: visual rating and volumetrics. Neurology 2004 1.46
40 The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old. Neurology 2007 1.46
41 FMRI of visual encoding: reproducibility of activation. Hum Brain Mapp 2000 1.46
42 White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer's disease, vascular dementia, and normal aging. J Neurol Neurosurg Psychiatry 1999 1.45
43 Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage 2002 1.44
44 Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 2001 1.43
45 Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology 2007 1.43
46 A case of macrocephaly, hydrocephalus, megacerebellum, white matter abnormalities and Rosenthal fibres. Dev Med Child Neurol 1993 1.41
47 Meningeal Gd-DTPA enhancement in multiple sclerosis. AJNR Am J Neuroradiol 1992 1.40
48 Pathophysiologic mechanisms in the development of age-related white matter changes of the brain. Dement Geriatr Cogn Disord 1998 1.40
49 A systematic review of Instrumental Activities of Daily Living scales in dementia: room for improvement. J Neurol Neurosurg Psychiatry 2009 1.39
50 [The immune system and Alzheimer's disease]. Tijdschr Psychiatr 2011 1.38
51 Behavioral symptoms in mild cognitive impairment. Neurology 2004 1.36
52 Hippocampal shape analysis in Alzheimer's disease: a population-based study. Neuroimage 2007 1.35
53 Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol 1996 1.35
54 Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. Neurology 2007 1.33
55 Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology 2012 1.31
56 CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology 2009 1.30
57 Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol 1998 1.30
58 Temporal lobe rating scale: application to Alzheimer's disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry 2001 1.26
59 Diabetes mellitus, hypertension and medial temporal lobe atrophy: the LADIS study. Diabet Med 2007 1.25
60 Regional distribution of white matter hyperintensities in vascular dementia, Alzheimer's disease and healthy aging. Dement Geriatr Cogn Disord 2004 1.22
61 Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old. Neurology 2010 1.22
62 Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease? J Neurol Neurosurg Psychiatry 2005 1.21
63 Within-subject reproducibility of visual activation patterns with functional magnetic resonance imaging using multislice echo planar imaging. Magn Reson Imaging 1998 1.21
64 EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol 2012 1.19
65 Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and multiple system atrophy patients. J Neurol Sci 1994 1.17
66 Reliability and sensitivity of visual scales versus volumetry for evaluating white matter hyperintensity progression. Cerebrovasc Dis 2008 1.17
67 Progression of cerebral white matter lesions in Alzheimer's disease: a new window for therapy? J Neurol Neurosurg Psychiatry 2005 1.17
68 Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology 1999 1.16
69 Epidemiology and risk factors of dementia. J Neurol Neurosurg Psychiatry 2005 1.16
70 Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002 1.14
71 Test-retest analysis with functional MR of the activated area in the human visual cortex. AJNR Am J Neuroradiol 1997 1.14
72 Parametric fMRI analysis of visual encoding in the human medial temporal lobe. Hippocampus 1999 1.13
73 Cognitive performance in type 1 diabetes patients is associated with cerebral white matter volume. Diabetologia 2007 1.11
74 Progression of cerebral white matter hyperintensities on MRI is related to diastolic blood pressure. Neurology 1998 1.11
75 Visual assessment of medical temporal lobe atrophy in demented and healthy control subjects: correlation with volumetry. Psychiatry Res 1999 1.11
76 Radiotherapy-induced cerebral abnormalities in patients with low-grade glioma. Neurology 2002 1.11
77 Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology 2009 1.10
78 Disrupted modular brain dynamics reflect cognitive dysfunction in Alzheimer's disease. Neuroimage 2011 1.10
79 Visual association encoding activates the medial temporal lobe: a functional magnetic resonance imaging study. Hippocampus 1997 1.09
80 Cerebral blood flow by using pulsed arterial spin-labeling in elderly subjects with white matter hyperintensities. AJNR Am J Neuroradiol 2008 1.09
81 Multicenter assessment of reliability of cranial MRI. Neurobiol Aging 2005 1.08
82 Role of white matter lesions in cognitive impairment of vascular origin. Alzheimer Dis Assoc Disord 2000 1.08
83 Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR Am J Roentgenol 1992 1.05
84 Whole-brain atrophy rate in Alzheimer disease: identifying fast progressors. Neurology 2008 1.05
85 Diabetic encephalopathy: A concept in need of a definition. Diabetologia 2006 1.05
86 Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe. Eur J Neurol 2009 1.04
87 Clinical significance of corpus callosum atrophy in a mixed elderly population. Neurobiol Aging 2006 1.04
88 Phase-contrast cine MR imaging of normal aqueductal CSF flow. Effect of aging and relation to CSF void on modulus MR. Acta Radiol 1994 1.03
89 Magnetoencephalographic analysis of cortical activity in Alzheimer's disease: a pilot study. Clin Neurophysiol 2000 1.02
90 Intrathecal chemokine levels in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2006 1.02
91 New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population. Dement Geriatr Cogn Disord 2010 1.01
92 Improved reliability of hippocampal atrophy rate measurement in mild cognitive impairment using fluid registration. Neuroimage 2006 1.01
93 Relationship between baseline white-matter changes and development of late-life depressive symptoms: 3-year results from the LADIS study. Psychol Med 2009 1.01
94 Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 1991 1.00
95 Limitations of clinical criteria for the diagnosis of vascular dementia in clinical trials. Is a focus on subcortical vascular dementia a solution? Ann N Y Acad Sci 2000 1.00
96 Development of screening guidelines and clinical criteria for predementia Alzheimer's disease. The DESCRIPA Study. Neuroepidemiology 2008 1.00
97 Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment. Neurology 2009 0.99
98 Neurocardiovascular instability, hypotensive episodes, and MRI lesions in neurodegenerative dementia. Ann N Y Acad Sci 2000 0.99
99 The diagnostic value of electroencephalography in mild senile Alzheimer's disease. Clin Neurophysiol 1999 0.99
100 Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr Med Res Opin 2008 0.98
101 Mutation frequency of PRKAR1B and the major familial dementia genes in a Dutch early onset dementia cohort. J Neurol 2014 0.98
102 Anterior medial temporal lobe activation during attempted retrieval of encoded visuospatial scenes: an event-related fMRI study. Neuroimage 2001 0.98
103 Most rapid cognitive decline in APOE epsilon4 negative Alzheimer's disease with early onset. Psychol Med 2009 0.98
104 White matter changes contribute to corpus callosum atrophy in the elderly: the LADIS study. AJNR Am J Neuroradiol 2008 0.97
105 Sporadic Creutzfeldt-Jakob disease in a young Dutch valine homozygote: atypical molecular phenotype. Ann Neurol 2001 0.97
106 Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease. J Neural Transm (Vienna) 2003 0.96
107 Medial temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS study. J Neurol Neurosurg Psychiatry 2005 0.96
108 EFNS task force: the use of neuroimaging in the diagnosis of dementia. Eur J Neurol 2012 0.95
109 Visual rating of hippocampal atrophy: correlation with volumetry. J Neurol Neurosurg Psychiatry 1994 0.95
110 MR of the spinal cord in multiple sclerosis: relation to clinical subtype and disability. AJNR Am J Neuroradiol 1997 0.95
111 The functional basis of ocular dominance: functional MRI (fMRI) findings. Neurosci Lett 1996 0.94
112 White matter hyperintensities and medial temporal lobe atrophy in clinical subtypes of mild cognitive impairment: the DESCRIPA study. J Neurol Neurosurg Psychiatry 2009 0.92
113 MRI volumetric correlates of white matter lesions in dementia with Lewy bodies and Alzheimer's disease. Int J Geriatr Psychiatry 2000 0.92
114 Loss of frontal fMRI activation in early frontotemporal dementia compared to early AD. Neurology 2003 0.91
115 Small vessel versus large vessel vascular dementia: risk factors and MRI findings. J Neurol 2008 0.91
116 Visualizing brain activation during planning: the tower of London test adapted for functional MR imaging. AJNR Am J Neuroradiol 2000 0.91
117 Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. Neuroradiology 1994 0.90
118 Serial quantitative MR assessment of optic neuritis in a case of neuromyelitis optica, using Gadolinium- "enhanced" STIR imaging. Neuroradiology 1991 0.90
119 Neuro-imaging in the diagnosis of Alzheimer's disease. II. Positron and single photon emission tomography. Clin Neurol Neurosurg 1993 0.90
120 Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychol Med 2012 0.90
121 Apolipoprotein E epsilon4 allele, temporal lobe atrophy, and white matter lesions in late-life dementias. Arch Neurol 1999 0.90
122 Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus. J Neurol Neurosurg Psychiatry 2006 0.89
123 Distribution of APOE genotypes in a memory clinic cohort. Dement Geriatr Cogn Disord 2008 0.88
124 Neuropsychological correlates of a right unilateral lacunar thalamic infarction. J Neurol Neurosurg Psychiatry 1999 0.88
125 Vascular dementia: the role of cerebral infarcts. Alzheimer Dis Assoc Disord 2000 0.88
126 Pre-and post-mortem MR imaging of unsuspected multiple sclerosis in a patient with Alzheimer's disease. J Neurol Sci 1993 0.88
127 Raloxifene affects brain activation patterns in postmenopausal women during visual encoding. J Clin Endocrinol Metab 2001 0.87
128 Evidence for atrophy of the corpus callosum in Alzheimer's disease. Eur Neurol 1994 0.87
129 EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease. Eur J Neurol 2015 0.87
130 Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J Biol Psychiatry 2005 0.87
131 Impact of diagnostic disclosure in dementia on patients and carers: qualitative case series analysis. Aging Ment Health 2006 0.86
132 CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. Neurology 2009 0.86
133 Imaging of static brain lesions in vascular dementia: implications for clinical trials. Alzheimer Dis Assoc Disord 2000 0.86
134 Visual activation patterns in patients with optic neuritis: an fMRI pilot study. Neurology 1998 0.86
135 Cognitive slowing in multiple sclerosis is strongly associated with brain volume reduction. Mult Scler 2006 0.86
136 A new rapid landmark-based regional MRI segmentation method of the brain. J Neurol Sci 2002 0.86
137 The use of neuropsychological tests across Europe: the need for a consensus in the use of assessment tools for dementia. Eur J Neurol 2011 0.86
138 Functional MRI of visual cortex in sedated 18 month-old infants with or without periventricular leukomalacia. Dev Med Child Neurol 2001 0.85
139 Physical activity and white matter lesion progression: assessment using MRI. Neurology 2007 0.85
140 Early diagnostic indices for the prevention of Alzheimer's disease. Ann Med 1998 0.85
141 Progression of Alzheimer disease in Europe: data from the European ICTUS study. Curr Alzheimer Res 2012 0.85
142 Efficacy of a medical food on cognition in Alzheimer's disease: results from secondary analyses of a randomized, controlled trial. J Nutr Health Aging 2011 0.85
143 Is the whole brain periventricular? J Neurol Neurosurg Psychiatry 2006 0.85
144 CSF tau and Abeta42 are not useful in the diagnosis of frontotemporal lobar degeneration. Neurology 2004 0.85
145 Self-perceived memory impairment and cognitive performance in an elderly independent population with age-related white matter changes. J Neurol Neurosurg Psychiatry 2007 0.85
146 Frontal lobe dysfunction in unilateral lenticulostriate infarcts. Prominent role of cortical lesions. Arch Neurol 1992 0.84
147 L-glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients. J Neural Transm (Vienna) 2000 0.84
148 Gadopentetate dimeglumine enhancement of multiple sclerosis lesions on long TR spin-echo images at 0.6 T. AJNR Am J Neuroradiol 1992 0.84
149 Hippocampal sulcus width and cavities: comparison between patients with Alzheimer disease and nondemented elderly subjects. AJNR Am J Neuroradiol 2006 0.83
150 Clinically silent dysfunction of dorsal columns and dorsal spinocerebellar tracts in hereditary spastic paraparesis. J Neurol Sci 1994 0.82
151 Progressive dementia and mesiotemporal atrophy on brain MRI: neurosyphilis mimicking pre-senile Alzheimer's disease? Eur J Neurol 2007 0.82
152 Methotrexate induced brain necrosis and severe leukoencephalopathy due to disconnection of an Ommaya device. J Neurooncol 1993 0.82
153 SPECT, CT and MRI in a Turkish family with Huntington's disease. Neuroradiology 1993 0.81
154 Genetic and biochemical markers for Alzheimer's disease: recent developments. Ann Clin Biochem 2000 0.81
155 Medial temporal lobe atrophy in an open population of very old persons: cognitive, brain atrophy, and sociomedical correlates. Neurology 1995 0.81
156 Decreased cerebrospinal fluid amyloid beta (1-40) levels in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry 2007 0.81
157 The use of EEG in the diagnosis of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2007 0.81
158 CSF biomarkers in frontotemporal lobar degeneration: relations with clinical characteristics, apolipoprotein E genotype, and neuroimaging. J Neurol Neurosurg Psychiatry 2006 0.80
159 The auditory oddball paradigm in patients with vascular cognitive impairment: a prolonged latency of the N2 complex. Dement Geriatr Cogn Disord 2006 0.80
160 Associations between patterns of EEG abnormalities and diagnosis in a large memory clinic cohort. Dement Geriatr Cogn Disord 2008 0.80
161 Cerebrospinal fluid ferritin levels of patients with Parkinson's disease, Alzheimer's disease, and multiple system atrophy. J Neural Transm Park Dis Dement Sect 1994 0.80
162 Protocols to demonstrate slowing of Alzheimer disease progression. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. The Disease Progression Sub-Group. Alzheimer Dis Assoc Disord 1997 0.80
163 An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion. AJNR Am J Neuroradiol 2013 0.79
164 A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Neurology 1992 0.79
165 Magnetic resonance imaging differences between dementia with Lewy bodies and Alzheimer's disease: a pilot study. Psychol Med 1999 0.79
166 Comparison of four potential MR parameters for severe tissue destruction in multiple sclerosis lesions. Magn Reson Imaging 1997 0.79
167 Distortions in rest-activity rhythm in aging relate to white matter hyperintensities. Neurobiol Aging 2007 0.79
168 Alzheimer's disease--one clinical syndrome, two radiological expressions: a study on blood pressure. J Neurol Neurosurg Psychiatry 2004 0.79
169 Angiotropic intravascular large-cell lymphoma with massive cerebral extension. J Neurol Neurosurg Psychiatry 1993 0.79
170 Medial temporal lobe atrophy scores translated to clinical practice: editorial comment on 'influence of age, disease onset and ApoE4 on visual medial temporal lobe atrophy cut-offs'. J Intern Med 2014 0.79
171 Intravenous immunoglobulins: a treatment for Alzheimer's disease? J Neurol Neurosurg Psychiatry 2004 0.78
172 Re-evaluation of cerebrospinal fluid angiotensin-converting enzyme activity in patients with 'probable' Alzheimer's disease. Eur J Clin Chem Clin Biochem 1993 0.78
173 Relationships between white matter hyperintensities, cerebral amyloid angiopathy and dementia in a population-based sample of the oldest old. Curr Alzheimer Res 2013 0.78
174 White-matter lesions on CT in Alzheimer patients. Acta Neurol Scand 1991 0.77
175 Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer's disease: secondary analyses from a randomized, controlled trial. J Nutr Health Aging 2011 0.77
176 The effect of anxiety and depression on decline of memory function in Alzheimer's disease. Int Psychogeriatr 2009 0.77
177 The influence of coincidental vascular pathology on symptomatology and course of Alzheimer's disease. J Neural Transm Suppl 1998 0.77
178 Diagnosing Alzheimer's disease in community-dwelling elderly: a comparison of EEG and MRI. Dement Geriatr Cogn Disord 1997 0.77
179 Nonlinear changes in brain activity during continuous word repetition: an event-related multiparametric functional MR imaging study. AJNR Am J Neuroradiol 2007 0.76
180 Use of laboratory and imaging investigations in dementia. J Neurol Neurosurg Psychiatry 2005 0.76
181 rCBF SPECT in Parkinson's disease patients with mental dysfunction. J Neural Transm Suppl 1997 0.76
182 [Development of memory clinics in The Netherlands]. Tijdschr Gerontol Geriatr 2007 0.76
183 An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels. Exp Neurol 2009 0.76
184 Neurological signs in relation to white matter hyperintensity volumes in memory clinic patients. Dement Geriatr Cogn Disord 2010 0.75
185 No evidence for abnormalities in kinetics of platelet monoamine oxidase in Alzheimer's disease. Clin Chim Acta 1995 0.75
186 [Cholinesterase inhibitors for Alzheimer disease: preliminary recommendations for treatment. Dutch Society for Psychiatry, Section of Geriatric Psychiatry]. Ned Tijdschr Geneeskd 1998 0.75
187 Intracranial ganglioglioma: MR imaging. AJR Am J Roentgenol 1990 0.75
188 Grey hair and grey matter. J Neurol Neurosurg Psychiatry 2004 0.75
189 Alzheimer's disease is not associated with altered concentrations of the nitric oxide synthase inhibitor asymmetric dimethylarginine in cerebrospinal fluid. J Neural Transm (Vienna) 2002 0.75
190 Serum alpha 1-antichymotrypsin is not a useful marker for Alzheimer's disease or dementia in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1993 0.75
191 [Cerebral white matter lesions in the elderly: vascular risk factors and cognitive consequences]. Ned Tijdschr Geneeskd 2002 0.75
192 Normal cerebrospinal fluid glutathione concentrations in Parkinson's disease, Alzheimer's disease and multiple system atrophy. J Neurol Sci 1999 0.75
193 NINDS AIREN neuroimaging criteria do not distinguish stroke patients with and without dementia. Neurology 2005 0.75
194 (99mTc)-HM-PAO SPECT and dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 1992 0.75
195 [Vascular dementia]. Ned Tijdschr Geneeskd 1990 0.75
196 Diagnostic criteria for dementia in clinical trials. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997 0.75
197 Aggression and multiple sclerosis. Br J Psychiatry 1991 0.75
198 Knowing the natural course of biomarkers in AD: longitudinal MRI, CSF and PET data. J Nutr Health Aging 2009 0.75
199 A four-generation Dutch family with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), linked to chromosome 19p13. Clin Neurol Neurosurg 1995 0.75
200 Clinical neurophysiology in the diagnosis of Alzheimer's disease. Clin Neurol Neurosurg 1994 0.75
201 No evidence for increased self-reported cognitive failure in Type 1 and Type 2 diabetes: a cross-sectional study. Diabet Med 2007 0.75
202 [DNA diagnostics in dementia]. Ned Tijdschr Geneeskd 2017 0.75
203 Autosomal recessive paraparesis with amyotrophy of the hands and feet. Acta Neurol Scand 1993 0.75
204 Regional differences in effects of APOE ε4 on cognitive impairment in non-demented subjects. Dement Geriatr Cogn Disord 2011 0.75
205 [Morphological imaging in the diagnosis of dementia. II. Vascular dementia]. Rev Med Interne 1995 0.75
206 Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential. J Prev Alzheimers Dis 2017 0.75
207 [The development of memory clinics in The Netherlands]. Ned Tijdschr Geneeskd 2007 0.75
208 Cerebrospinal fluid acetylcholinesterase homospecific activity in patients with "probable Alzheimer's disease". Biol Psychiatry 1994 0.75
209 [Chronic traumatic encephalopathy: an old acquaintance in athletes]. Ned Tijdschr Geneeskd 2017 0.75
210 Intracerebral haemorrhage in Sneddon's syndrome. J Neurol Sci 1992 0.75
211 [Drugs for Alzheimer disease: what will the minister decide]. Tijdschr Gerontol Geriatr 1998 0.75
212 Cooperation and networking on white matter disorders: the European Task Force on Age-Related White Matter Changes. Dement Geriatr Cogn Disord 1998 0.75